Vircon Legal advised HippocrApp — the project later rebranded globally as Medklik — on its angel financing round. The round closed on 29 April 2021 with participation from B4YO Capital alongside individual angel investors. The size of the transaction was not disclosed at the request of the parties.
Healthcare and clinician-facing digital products carry structural considerations that distinguish them from pure consumer or pure SaaS rounds — regulatory perimeters that vary materially by target market, clinical workflow integration requirements, data sensitivity that intersects with multi-jurisdictional privacy regimes, and product trajectories that depend on credible clinician adoption rather than pure consumer growth. Angel and seed rounds funding healthcare-adjacent products need to be structured with these realities in mind: the cap table has to support the longer product validation horizon, the documentation needs to align with the operating reality of a regulated product, and the governance architecture has to accommodate the specialized expertise that healthcare-focused investors typically expect to contribute.
Vircon Legal advised on transaction structuring, subscription documentation, valuation mechanics, governance and reserved-matter design between the institutional and individual angel participants, founder commitments, IP assignment frameworks calibrated for healthcare data and clinician workflows, and the post-closing corporate housekeeping required after the change in shareholder composition. The presence of an institutional anchor like B4YO Capital alongside individual angels in the round provided the company with both capital and the structured discipline that later financing rounds — and the eventual global rebrand to Medklik — would build on.
For more on our early-stage and angel-round practice, see our Startup Law and Sell-Side Representation pages. For data privacy considerations relevant to healthcare-adjacent products, see our KVKK & GDPR Compliance practice.
